Abstracts tagged "Data analysis"

Abstract Number: 119 • 2020 Pediatric Rheumatology Symposium
Actual Medication Usage of Patients with Juvenile Onset Systemic Lupus Erythematosus Using Japanese Health Insurance Database
Takayuki Kishi¹, Takako Miyamae ², Ryoko Sakai ³, Yumi Tani ², Satoru Nagata ¹ and Masayoshi Harigai ³, ¹Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan, ²Pediatric Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Background: Immunosuppressive therapy is the mainstay of treatment of child systemic lupus erythematosus (cSLE). However until very recently, the treatment of cSLE lacked uniformity.…
Abstract Number: 2764 • 2018 ACR/ARHP Annual Meeting
Incidence, Characteristics and Management of Giant Cell Arteritis in France: A Study Based on National Health Insurance Claims Data
Valérie Devauchelle-Pensec¹, Eric Hachulla², Marc Paccalin³, Sophie Gandon⁴, Isabelle Idier⁵, Maeva Nolin⁶, Manon Belhassen⁶ and Alfred Mahr⁷, ¹Department of Rheumatology and Unit of Immunology, University Medical School, Brest, France, ²Department of Internal Medicine, University Lille Nord-de-France, Lille, France, ³Department of Geriatric Medicine, University Hospital, Poitiers, France, ⁴Clinical Operation, Roche SAS, Boulogne-Billancourt, France, ⁵Medical department, Chugai Pharma France, Paris La Defense, France, ⁶PELyon, Pharmacoepidemiologie, Lyon, France, ⁷Hospital Saint-Louis, University Paris Diderot, Paris, France
Background/Purpose: Giant cell arteritis (GCA) is an immune-mediated, primary systemic vasculitis that affects large and medium-sized arteries. GCA may cause vision loss in up to…
Abstract Number: 2856 • 2018 ACR/ARHP Annual Meeting
Do Patients with Moderate or High Disease Activity Escalate RA Therapy According to Treat-to-Target Principles? Results from the Acr’s RISE Registry
Huifeng Yun¹, Lang Chen¹, Fenglong Xie¹, Himanshu Patel², Natalie Boytsov², Xiang Zhang² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Routine measurement of RA disease activity and adjustment of drug therapy to attain remission or low disease activity is recommended by the ACR and…
Abstract Number: 1660 • 2018 ACR/ARHP Annual Meeting
Depression Has a Greater Impact on Psoriatic Arthritis Than Rheumatoid Arthritis
Surjeet Dheer¹, Vivekanand Tiwari², Ammarah Hussain¹, Kakageldi Hommadov¹, Ana Maheshwari¹ and Martin J. Bergman³, ¹Mercy Catholic Medical Center, Philadelphia, PA, ²St John's Hospital, Springfield, IL, ³Drexel University College of Medicine, Philadelphia, PA
Background/Purpose: Depression has been shown to be more common in patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA), than in the general population. The…
Abstract Number: 212 • 2017 ACR/ARHP Annual Meeting
Treatment Patterns in Large Vessel Arteritis (Giant Cell Arteritis and Temporal Arteritis): Findings from a Large Contemporaneous Real-World Cohort in the US
Zhaohui Su¹, Vandana Menon¹, Richard Gliklich² and Tom Brecht¹, ¹Research, OM1, Inc, Cambridge, MA, ²OM1, Inc, Cambridge, MA
Background/Purpose: Giant cell arteritis (GCA) is the most common form of primary systemic vasculitis with annual incidence as high as 27 per 100,000 in persons…
Abstract Number: 1014 • 2017 ACR/ARHP Annual Meeting
The Rheumatic Disease Data Refinery: A Case Study in Integrative Genomics Reveals Complex IFN Signatures in Therapeutic Studies in SLE
Jaclyn N Taroni and Casey S. Greene, Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Over the past 15 years, more than 10,000 whole tissue biopsies from patients with rheumatic diseases have been deposited into publicly available gene expression…
Abstract Number: 1019 • 2017 ACR/ARHP Annual Meeting
Molecular Profiling of RA Patients Suggests a Differential Involvement of Adaptive and Innate Cell Populations in Response to Anti-TNF Treatment
Victor Farutin¹, Thomas Prod'homme¹, Kevin McConnell¹, Nathaniel Washburn¹, Patrick Halvey¹, Jamey Guess¹, Nur Sibel Gunay¹, Jan Hillson², Carol J. Etzel³, Katherine C. Saunders³, Dimitrios A. Pappas^3,4, Anthony Manning¹, Leona Ling¹ and Ishan Capila¹, ¹Research, Momenta Pharmaceuticals, Inc., Cambridge, MA, ²Clinical Research, Momenta Pharmaceuticals, Inc., Cambridge, MA, ³Corrona, LLC, Southborough, MA, ⁴Columbia University, New York, NY
Background/Purpose: Despite the success of anti-TNF therapies in RA, ~ 30 % of patients are non-responders. Several studies have focused on understanding the biology underlying…
Abstract Number: 1712 • 2017 ACR/ARHP Annual Meeting
Microbial and Metabolic MULTI-Omic Correlations in Systemic Sclerosis Patients
Chiara Bellocchi¹, Alvaro Fernández-Ochoa², Gaia Montanelli¹, Barbara Vigone³, Alessandro Santaniello³, Christian Milani⁴, Rosa Quirantes-PIné², Isabel Borras Linares², Marco Ventura⁴, Antonio Segura Carretero², Marta Alarcón-Riquelme^5,6 and Lorenzo Beretta³, ¹Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy, ²Department of Analytical Chemistry, University of Granada, Granada, Spain, ³Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ⁴Department of Life Sciences, Università degli studi di Parma, Parma, Italy, ⁵Centro de Genómica e Investigación Oncológica (GENYO), Pfizer-Universidad de Granada-Junta de Andalucía, Granada, Spain, ⁶Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The gastro-intestinal tract (GIT) is frequently involved in Systemic sclerosis (SSc). Perturbation in the gut microbiota may affect the body well-being and function and…
Abstract Number: 1780 • 2017 ACR/ARHP Annual Meeting
Prognostic Factors in Patients with Granulomatosis with Polyangiitis Requiring Hospitalization- a 10 Year Nationwide Analysis
Yumeng Wen¹, Yiming Luo¹ and Changchuan Jiang², ¹Department of Medicine, Mount Sinai St Luke's and Mount Sinai West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ²Department of Medicine, Mount Sinai St. Luke's West Hospitals. Icahn School of Medicine at Mount Sinai., New York, NY
Background/Purpose: Granulomatosis with Polyangiitis (GPA) is a form of systemic vasculitis with necrotizing granulomatous inflammation commonly involving upper and lower respiratory tracts, necrotizing glomerulonephritis and…
Abstract Number: 1865 • 2017 ACR/ARHP Annual Meeting
Novel Approach to Arthritis Surveillance Suggests a Much Higher Prevalence of Arthritis Among US Adults Than Previous Estimate
S. Reza Jafarzadeh and David T. Felson, Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Current national estimates of arthritis prevalence in the United States rely on a single survey question about doctor-diagnosed arthritis from the National Health Interview…
Abstract Number: 1964 • 2017 ACR/ARHP Annual Meeting
The Risk of Hydroxychloroquine Toxic Retinopathy and Its Risk Factors in the Treatment of Rheumatic Diseases: A Systematic Review
April Jorge¹, Sharan K. Rai² and Hyon K. Choi², ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is widely used in the treatment of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and other rheumatic diseases. While generally well-tolerated and…
Abstract Number: 2827 • 2017 ACR/ARHP Annual Meeting
A Novel Statistical Method to Resolve Cellular Heterogeneity in Disease Tissues: Integrating Transcriptomic Data in Accelerating Medicines Partnership (AMP) – RA Network Phase 1 Data
Fan Zhang¹, Kamil Slowikowski², Chamith Fonseka¹, Kevin Wei³, Maria Gutierrez-Arcelus⁴, James Lederer⁵, Nir Hacohen⁶, Vivian P. Bykerk⁷, Michael Holers⁸, Peter Gregersen⁹, Mandy J. McGeachy¹⁰, Larry W. Moreland¹¹, Andrew Filer¹², Costantino Pitzalis¹³, Yvonne C. Lee¹⁴, Jennifer H. Anolik¹⁵, Michael Brenner⁴ and Soumya Raychaudhuri¹⁶, ¹Divisions of Genetics and Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical Schoo, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Harvard Medical School, Boston, MA, ⁷2-005, Mt Sinai Hospital, Toronto, ON, Canada, ⁸Medicine, Division of Rheumatology, University of Colorado Denver, Aurora, CO, ⁹The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, ¹⁰Medicine, University of Pittsburgh, Pittsburgh, PA, ¹¹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹²Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom, ¹³Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ¹⁴Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁵Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ¹⁶Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Detecting distinct cellular subsets in disease tissues is key to understanding the pathogenesis of immune diseases, for example in synovial tissues in rheumatoid arthritis…
Abstract Number: 2910 • 2017 ACR/ARHP Annual Meeting
Comparison of Clinical and Ultrasound Measures of Disease Activity in a Large National ‘Real Life’ Cohort of RA Patients
Pascal Zufferey¹, Delphine Couvoisier², Hans Ruedi Ziswiler³, Laure Brulhart⁴, Giorgio Tamborrini⁵, Michael Nissen⁶, Adrian Ciurea⁷, Burkhard Moeller⁸, Maria Antonietta D'Agostino^9,10 and Axel Finckh², ¹Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, ²geneva university hospital, Geneva, Switzerland, ³Osteorheuma, Bern, Switzerland, ⁴médecine, hôpital neuchateulois, La chaux de fond, Switzerland, ⁵UZR, Basel, Switzerland, ⁶rheumatology, geneva university hospital, Geneva, Switzerland, ⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁸Department for Rheumatology, Immunology and Allergology, University Hospital of Bern, Bern, Switzerland, ⁹Department of Rheumatology, Assistance publique-Hôpitaux de Paris Ambroise Paré Hospital, Boulogne-Billancourt , Université Versailles Saint Quentin en Yvelines, Paris, France, ¹⁰University of Paris, Paris, France
Background/Purpose: Clinical measures of disease activity, such as the DAS-score and ultrasound (US) scores of disease activity can be sometimes yield discordant results. Little research…
Abstract Number: 2923 • 2017 ACR/ARHP Annual Meeting
A Propensity Score-Matched Study of Organ Damage in Patients with Systemic Lupus Erythematosus from the BLISS Long-Term Extension Trials Versus the Toronto Lupus Cohort: A Post Hoc Longitudinal Analysis
Murray Urowitz¹, Robert L. Ohsfeldt^2,3, Ron Wielage³, Kari A. Kelton³, Yumi Asukai⁴ and Sulabha Ramachandran⁵, ¹Medicine, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Texas A&M University, Texas, TX, ³Medical Decision Modeling Inc., Indianapolis, IN, ⁴GSK, Uxbridge, Middlesex, United Kingdom, ⁵Value Evidence and Outcomes, GlaxoSmithKline, Renaissance Centre, PA
Background/Purpose: Two Phase 3, randomized controlled trials (BLISS 52/76) studied the efficacy and safety of belimumab plus standard of care (SoC) in systemic lupus erythematosus…
Abstract Number: 9 • 2017 Pediatric Rheumatology Symposium
Biologically-Based Approach for Classifying Chronic Childhood Arthritis
Elham Rezaei¹, Daniel Hogan², Brett Trost², Anthony Kusalik², Susanne Benseler³, Gilles Boire⁴, David A. Cabral⁵, Bonnie Cameron⁶, Sarah Campillo⁷, Gaëlle Chédeville⁸, Paul Dancey⁹, Ciarán M. Duffy¹⁰, Karen N Watanabe Duffy¹¹, Janet Ellsworth¹², Simon Eng¹³, Brian M. Feldman¹⁴, John Gordon², Jaime Guzman¹⁵, Kristin Houghton¹⁶, Adam Huber¹⁷, Quaid Morris¹³, Bianca Lang¹⁸, Deborah M. Levy¹⁹, Loren Matheson²⁰, Kiem Oen²¹, Ross Petty²², Suzanne Ramsey²³, Johannes Roth²⁴, Dax Rumsey²⁵, Claire Saint-Cyr²⁶, Rayfel Schneider²⁷, Rosie Scuccimarri²⁸, Earl Silverman¹⁹, Lynn R. Spiegel²⁹, Elizabeth Stringer¹⁸, Shirley M.L. Tse³⁰, Lori Tucker³¹, Rae S.M. Yeung³² and Alan Rosenberg¹, ¹Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ²University of Saskatchewan, Saskatoon, SK, Canada, ³Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ⁴Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁵Pediatrics/Rm K4-121, BC Children's Hospital, Vancouver, BC, Canada, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Montreal Children's Hospital, Montreal, QC, Canada, ⁸Rheumatology, McGill University, Montreal, QC, Canada, ⁹Pediatrics, Janeway Children's Hospital, St. John's, NL, Canada, ¹⁰Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ¹¹Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ¹²University of Alberta, Edmonton, AB, Canada, ¹³University of Toronto, Toronto, ON, Canada, ¹⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁵Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ¹⁶Rheumatology/Pediatrics, British Columbia Childrens Hos, Vancouver, BC, Canada, ¹⁷IWK Health Centre, Halifax, NS, Canada, ¹⁸Dalhousie University, Halifax, NS, Canada, ¹⁹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²⁰University of Saskatchewan, Ottawa, ON, Canada, ²¹University of Manitoba, Winnipeg, MB, Canada, ²²Pediatric Rheumatology, Division of Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ²³Pediatric Rheumatology, IWK Health Centre, Halifax, NS, Canada, ²⁴Pediatric Rheumatology, Children's Hospital Eastern On, Ottawa, ON, Canada, ²⁵Stollery Children's Hospital, Edmonton, AB, Canada, ²⁶Pediatrics, CHU Sainte-Justine, Montreal, QC, Canada, ²⁷Division of Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ²⁸Division of Pediatric Rheumatology, Montreal Children's Hospital/McGill University Health Centre, Montreal, QC, Canada, ²⁹Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ³⁰Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ³¹Pediatric Rheum/Rm K4-120, BC Childrens Hospital, Vancouver, BC, Canada, ³²Paediatrics, Immunology and Medical Science, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) comprises a heterogeneous group of conditions that share chronic arthritis as a common characteristic. International uniformity in classifying JIA, based…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].